Continuing Medical Education Information

 

AACE Endocrine University

Event start date: 02/22/2024
Credit claim deadline: 12/31/2024

 

Statement of Need

Endocrine University® is designed to provide a forum for endocrinology fellows -in-training to enhance their endocrine curriculum, particularly in diabetes, thyroid, bone, and new technology which has become essential to the practice of endocrinology.

 

Target Audience:

This program is intended for first year Endocrine Fellows-in-Training.

 

Learning Objectives

By the end of the meeting, participants will be able to:

  • Effectively utilize new skills and technology in diabetes and thyroid ultrasound.
  • Apply the most up-to-date guidelines and evidence-based practices for the diagnosis and treatment of diabetes and thyroid disease.
  • Integrate the latest evidence-based research for diagnosis and treatment of emerging areas of diabetes, thyroid, and bone related practice.

 

Accreditation and Designation Statements

The American College of Endocrinology (ACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Endocrinology (ACE) designates this other (live virtual) activity for a maximum of 16 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Commercial Support

This activity is supported by educational grants from the following:

  • Abbott Diabetes Care
  • Dexcom
  • Vertex Pharmaceuticals Inc
  • Corcept Therapeutics
  • Insulet Corporation
  • Medtronic
  • Novo Nordisk
  • Radius Health
  • Ultragenyx Pharmaceutical
  • Lilly USA, LLC
  • Recordati Rare Diseases

 

Disclosure and Conflicts of Interest Policy:

The American Association of Clinical Endocrinologists (AACE) remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of AACE to eliminate all situations of potential conflict of interest, but rather to enable those who are working with AACE to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the CME Subcommittee to ensure that such situations are properly evaluated and, if necessary, resolved. AACE educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all AACE accredited activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities.

 

Planning Committee Disclosures

Planner Name

Sara E. Lubitz, MD, FACE

Ineligible Company

Ascendis
Eli Lilly
Hologic
Takeda
Amryt

Relevant Financial Relationship

Site PI Research funding
Stock Ownership
Stock Ownership
Site PI Research Funding
Site PI Research Funding


Planner Name

Matthew J. Levine, MD, FACE

Ineligible Company

Mannkind
Recordati
Novo Nordisk

Relevant Financial Relationship

Consultant
Consultant
Speakers Bureau


Planner Name

Geetha Gopalakrishnan, MD, FACE

Ineligible Company

Medtronic
Sparrow and Spruce

Relevant Financial Relationship

Research Funding
Research Funding

All of the relevant financial relationships listed for these individuals have been mitigated. All other planners for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.


 

 

Faculty Disclosures

Faculty Name

Guillermo Umpierrez, MD, MACP, CDCES, FACE

Ineligible Company

Abbott
American Diabetes Association
AstraZeneca
Bayer
Dexcom
Glycare

Relevant Financial Relationship

Research Funding
BOD/EC
Research Funding
Research Funding
Research Funding
Consultant


Faculty Name

Silvio Inzucchi, MD

Ineligible Company

Abbott
AstraZeneca
Boehringer-Ingelheim
Esperion
Lexicon
Merck/Pfizer
Novo Nordisk
VTV Therapeutics

Relevant Financial Relationship

Consultant
Consultant
Consultant
Consultant
Consultant
Consultant
Consultant
Consultant


Faculty Name

William Polonsky, PhD, CDE

Ineligible Company

Abbott Diabetes Care
Dexcom
Sanofi
Embecta

Relevant Financial Relationship

Research Funding
Research Funding
Consultant
Consultant


Faculty Name

Dace Trence, MD, MACE

Ineligible Company

Medtronic
Sanofi

Relevant Financial Relationship

Stock Ownership
Stock Ownership


Faculty Name

Richard E. Pratley, MD

Ineligible Company

Bayer AG
Corcept Therapeutics Inc.
Dexcom
Gasherbaum Bio, Inc.
Hanmi Pharmaceutical Co.
Hengrui (USA) Ltd.
Merck
Metavention
Novo Nordisk
Pfizer
Rivus Pharmaceuticals Inc.
Sanofi
Scohia Pharma Inc.
Sun Pharmaceutical Industries

Relevant Financial Relationship

Consultant
Consultant
Consultant
Consultant
Consultant
Consultant
Consultant
Research Funding
Research Funding/Consultant
Consultant
Consultant
Consultant
Consultant
Consultant


Faculty Name

Archana Sadhu, MD, FACE

Ineligible Company

Abbott Laboratories

Relevant Financial Relationship

Consultant


Faculty Name

Nadine Palermo, DO

Ineligible Company

Dexcom

Relevant Financial Relationship

Research Funding


Faculty Name

Elias Siraj, MD, FACE, FACP

Ineligible Company

Boehringer-Ingelheim/Eli Lilly alliance
Novo Nordisk

Relevant Financial Relationship

Consultant/Speakers Bureau
Research Funding/Consultant/Speakers Bureau


Faculty Name

David Ahn, MD

Ineligible Company

Ascensia Diabetes Care
Lilly Diabetes
Mannkind
Novo Nordisk
Roche Diagnostics
Xeris Pharmaceuticals

Relevant Financial Relationship

Advisory Board
Advisory Board; Speakers Bureau
Advisory Board
Speakers Bureau
Advisory Board
Speakers Bureau


Faculty Name

Mimi Hu, MD

Ineligible Company

Up To Date
Medullary Thyroid Cancer Consortium Registry
Eli Lilly
Medical Education Resources

Relevant Financial Relationship

Stock Ownership
Stock Ownership
Stock Ownership; Research funding
Stock Ownership


Faculty Name

Trevor Angell, MD

Ineligible Company

Immunovant, Inc.

Relevant Financial Relationship

Research Funding


Faculty Name

Benjamin Gigliotti, MD

Ineligible Company

Immunovant, Inc.
Horizon Pharmaceuticals

Relevant Financial Relationship

Consultant
Consultant


Faculty Name

Raymon H. Grogan, MD

Ineligible Company

Medtronic

Relevant Financial Relationship

Consultant


Faculty Name

Steven Petak, MD, JD, MACE, FACP

Ineligible Company

Alexion
Amgen

Relevant Financial Relationship

Speaker Bureau
Speaker Bureau


Faculty Name

Geetha Gopalakrishnan, MD, FACE

Ineligible Company

Medtronic
Sparrow and Spruce

Relevant Financial Relationship

Research Funding
Research Funding


Faculty Name

Michael Lewiecki, MD, FACE

Ineligible Company

Amgen
Radius

Relevant Financial Relationship

Stock Ownership/Research Funding/Speakers Bureau/Consultant
Stock Ownership/Research Funding

 

All of the relevant financial relationships listed for these individuals have been mitigated. All other faculty for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Reviewers

None of the reviewers for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.